AKBA: Nilai perusahaan marang bathi resik Akebia

Lambang korporat lan logo Akebia (AKBA)

The investment potential of Akebia Therapeutics (AKBA) is bolstered by the implementation of energy-saving technologies and emission filtration in its laboratories. The business's current P/E ratio illustrates the stock price dynamics relative to earnings, where -2.50 captures the current value of the indicator. Efficiency is confirmed by the scaling of Vafseo sales through Medicare, while the cyclical recovery phase and regulatory successes ensure stable revenue growth.

Akebia Therapeutics, Inc. (AKBA): Pangali P/E saka 04.07.2022 nganti 18.11.2026

Rincian analitis perusahaan Akebia Therapeutics

- rega lan prakiraan konsensus rega:
- informasi kapitalisasi pasar:
Ringkesan analisis perusahaan:AKBA (Akebia)
Sampel barang akebia.com

High scalability of kidney disease treatments with minimal costs allows Akebia Therapeutics (AKBA) to generate significant cash flow. The ratio of market capitalization to net income, represented by the price-to-earnings ratio, measures the cost of one dollar of earnings, helping investors identify asset overvaluation or hidden delisting risks in the event of a sharp decline in the multiple.